Pharmaceutical

EC grants orphan medicinal product status to Rocket’s RP-A601

The EC has granted orphan medicinal product designation for Rocket Pharmaceuticals’ RP-A601 for PKP-2 related arrhythmogenic cardiomyopathy.

May 31, 2024 - 04:00
EC grants orphan medicinal product status to Rocket’s RP-A601
The EC has granted orphan medicinal product designation for Rocket Pharmaceuticals’ RP-A601 for PKP-2 related arrhythmogenic cardiomyopathy.
Read the original article

Tags:

Previous Article

AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs

Next Article

FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

When is a Wall Street disappointment ‘good enough’ for the FDA?

When is a Wall Street disappointment ‘good enough’ for ...

Oct 4, 2023

Iovance’s PDUFA date for lifileucel pushed due to FDA backlog

Iovance’s PDUFA date for lifileucel pushed due to FDA b...

Sep 15, 2023

AlgoTx unveils plans for Phase II trial for rare chronic condition

AlgoTx unveils plans for Phase II trial for rare chroni...

Mar 29, 2023